Showing results (61-70 of 186) with videos related to
Sort By:
Pageof 19
Transplantation and Cellular Therapy|April 25, 2021
Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective AnalysisAndrew J Cowan, Philip A Stevenson, Damian J Green, et al.Blood|January 7, 2009
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinationsJohn M Pagel, Nural Orgun, Donald K Hamlin, et al.Leukemia & Lymphoma|July 28, 2021
Idelalisib immune-related toxicity is associated with improved treatment responseNina D Wagner-Johnston, Jeff Sharman, Richard R Furman, et al.Clinical Lymphoma, Myeloma & Leukemia|May 28, 2020
KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell TransplantationAndrew J Cowan, Damian J Green, Mehdi Karami, et al.Leukemia & Lymphoma|October 6, 2007
The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantationGrant E Keeney, Ted A Gooley, Rosalyn N Pham, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphomaAjay K Gopal, Ted A Gooley, Joseph G Rajendran, et al.Leukemia & Lymphoma|June 11, 2014
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphomaTim Illidge, Reda Bouabdallah, Robert Chen, et al.British Journal of Haematology|May 27, 2009
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphomaAndres Forero-Torres, John P Leonard, Anas Younes, et al.Blood|February 17, 2007
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomasAnastasia Pantelias, John M Pagel, Nathan Hedin, et al.Journal of Clinical Pharmacology|June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignanciesTae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.Pageof 19